Lasmiditan Is a New Option for Acute Migraine Treatment.
Nurs Womens Health
; 24(4): 294-299, 2020 Aug.
Article
em En
| MEDLINE
| ID: mdl-32663443
ABSTRACT
Lasmiditan is a new oral medication for treatment of acute migraine. It was approved by the U.S. Food and Drug Administration in October 2019 and is marketed under the brand name Reyvow (Eli Lilly and Company, Indianapolis, IN). It is the first of its kind in a new drug class called ditans. Lasmiditan has been studied as monotherapy for acute migraine treatment and as an abortive therapy for adults taking chronic migraine preventive medication. Lasmiditan may be an option for individuals who have had no relief with triptans or other acute migraine treatment agents or who are unable to use other migraine treatments because of contraindications.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Piridinas
/
Benzamidas
/
Agonistas do Receptor de Serotonina
/
Transtornos de Enxaqueca
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article